Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire
Lists
Only you see this
Abstract
Ovarian cancers express highly immunogenic tissue-specific antigens. The resulting immune infiltration is a major prognostic factor. There is therefore a strong biological rationale for the development of immunotherapy in ovarian cancer. However, based on Phase I and II clinical trials data, the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (ICPIs) remains limited in monotherapy in heavily pre-treated patients. Currently, the identification of predictive biomarkers of response and resistance is one of the major areas of research. Identifying effective combination of anti-PD-1 or anti-PD-L1 with other anticancer agents is another clinical need. Several combinations were evaluated. The association of ICPIs with chemotherapy (anthracyclines or carboplatin+paclitaxel) is disappointing (JAVELIN studies). The association with PARP inhibitors, anti-angiogenic agents and CTLA-4 inhibitors seems promising. Other immune therapies such as cell therapies (adoptive transfer of intra-tumor lymphocytes, CAR T cells or vaccines from dendritic cells) could be the future of immunotherapy in ovarian cancer but only early phase studies clinical data is available at this time.
BibTeX
@article{saux2020les,
author = {Olivia Le Saux and Bertrand Dubois and Marc‐Henri Stern and Magali Terme and Éric Tartour and Jean‐Marc Classe and Nicolás Chopin and Olivier Trédan and Christophe Caux and Isabelle Ray‐Coquard},
title = {{Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire}},
journal = {Bulletin},
year = {2020},
doi = {10.1016/j.bulcan.2019.11.015},
}Loading related content...